Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 …

N Gasper-Smith, DM Crossman, JF Whitesides… - Journal of …, 2008 - Am Soc Microbiol
N Gasper-Smith, DM Crossman, JF Whitesides, N Mensali, JS Ottinger, SG Plonk…
Journal of virology, 2008Am Soc Microbiol
The death of CD4+ CCR5+ T cells is a hallmark of human immunodeficiency virus (HIV)
infection. We studied the plasma levels of cell death mediators and products—tumor
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas ligand, TNF receptor
type 2 (TNFR-2), and plasma microparticles—during the earliest stages of infection following
HIV type 1 (HIV-1) transmission in plasma samples from US plasma donors. Significant
plasma TRAIL level elevations occurred a mean of 7.2 days before the peak of plasma viral …
Abstract
The death of CD4+ CCR5+ T cells is a hallmark of human immunodeficiency virus (HIV) infection. We studied the plasma levels of cell death mediators and products—tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas ligand, TNF receptor type 2 (TNFR-2), and plasma microparticles—during the earliest stages of infection following HIV type 1 (HIV-1) transmission in plasma samples from U.S. plasma donors. Significant plasma TRAIL level elevations occurred a mean of 7.2 days before the peak of plasma viral load (VL), while TNFR-2, Fas ligand, and microparticle level elevations occurred concurrently with maximum VL. Microparticles had been previously shown to mediate immunosuppressive effects on T cells and macrophages. We found that T-cell apoptotic microparticles also potently suppressed in vitro immunoglobulin G (IgG) and IgA antibody production by memory B cells. Thus, release of TRAIL during the onset of plasma viremia (i.e., the eclipse phase) in HIV-1 transmission may initiate or amplify early HIV-1-induced cell death. The window of opportunity for a HIV-1 vaccine is from the time of HIV-1 transmission until establishment of the latently infected CD4+ T cells. Release of products of cell death and subsequent immunosuppression following HIV-1 transmission could potentially narrow the window of opportunity during which a vaccine is able to extinguish HIV-1 infection and could place severe constraints on the amount of time available for the immune system to respond to the transmitted virus.
American Society for Microbiology